The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ALEXIBIC (Alembic Pharmaceuticals Australia Pty Ltd)
Product name
ALEXIBIC
Date registered
Evaluation commenced
Decision date
Approval time
110 (255 working days)
Active ingredients
apixaban
Registration type
New generic medicine
Indication
ALEXIBIC is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery.
ALEXIBIC is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.
ALEXIBIC is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients.
ALEXIBIC is indicated for the prevention of recurrent DVT and PE in adult patients.